Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

CD137L (soluble) (human), (recombinant)

 
ALX-522-111-C010 10 µg 186.00 USD
 
ALX-522-111-3010 3x10 µg SuperPack 384.00 USD
Do you need bulk/larger quantities?
 
Replaces Prod. #: ALX-522-032

Biologically active CD137L (4-1BBL; TNFSF 9) comprising the whole extracellular tail domain (aa 49-93), which is important for the cross-linking of the protein that is essential for its biological activity.

Product Specification

Alternative Name:4-1BBL, TNFSF 9
 
MW:~27kDa
 
Source:Produced in HEK 293 cells. The extracellular domain of human CD137L (aa 49-254) is fused at the N-terminus to a linker peptide (10 aa) and a FLAG®-tag.
 
UniProt ID:P41274
 
Concentration:0.1mg/ml after reconstitution.
 
Formulation:Lyophilized. Contains PBS and 5% trehalose.
 
Purity:≥95% (SDS-PAGE)
 
Endotoxin Content:<0.1EU/µg purified protein (LAL test; Bio Whittaker).
 
Specificity:Binds to human CD137 (4-1BB).
 
Reconstitution:Reconstitute with 100µl sterile distilled water. Further dilutions should be made with medium containing 5% fetal calf serum.
 
Shipping:Shipped on Blue Ice
 
Long Term Storage:-20°C
 
Use/Stability:Stable for at least 6 months after receipt when stored at -20°C.
 
Handling:Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and store at -20°C.
 
Scientific Background:The CD137 ligand (CD137L, 4-1BBL) is a member of the tumor necrosis factor (TNF) family. CD137L is a type II, transmembrane protein found on activated macrophages, dendritic cells and mature B cells. The interaction with its receptor 4-1BB induces recruitment of TNF receptor-associated factor 1 (TRAF1) and TRAF2 and interaction with the kinase p56lck. CD137 and CD137L have been reported to be involved in tumor rejection, apoptosis, anti-viral immunity, diabetes, in T and B cell co-stimulation and modulation of the immune response.
 
Technical Info/Product Notes:FLAG is a registered trademark of Sigma-Aldrich Co.
 
522-111
Figure: Dose-dependent binding of recombinant human soluble CD137L to CD137:Fc (human). Recombinant human CD137L saturates its receptor at a concentration range of 2-4’000ng/ml. Method: Receptor binding assay: a 96-well ELISA plate was coated O/N with 50ng per well of CD137 (human):Fc (human) (rec.) (4-1BB:Fc) (Prod. No. ALX-522-031). After a blocking step, the indicated concentrations of rhsCD137L were added for 1 hour. After extensive washing, Enhancer for Ligands (Prod. No. ALX-804-034) was added for 1 hour. Bound ligand was revealed by a rabbit anti-mouse IgG-HRP (1:1’000 dilution, Jackson Immunoresearch) incubated for 1 hour. OPD (Sigma) was used as a substrate and absorbance was measured at 490nm in an ELISA reader.
Please mouse over
522-111

Product Literature References

Production of recombinant human trimeric CD137L (4-1BBL). Cross-linking is essential to its T cell co-stimulation activity: C. Rabu, et al.; J. Biol. Chem. 280, 41472 (2005), Abstract; Full Text

Product Toolbox

PRODUCT RESOURCES

Datasheet
MSDS
Certificate of Analysis

RELATED PRODUCTS

By target:
CD137L
By biological activity:
CD137L Recombinant protein
By catalog section:

PRODUCT SUPPORT

FAQs
Technical Service
Customer Service

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,